essence semaglutide in metabolic dysfunction-associated steatohepatitis. Congratulations Philip Newsome for your excellent presentation of the phase 3 trial results. 👉 Semaglutide demonstrates… Phase 3 ESSENCE trial: Semaglutide

How can apps help with protein tracking

In clinical trials, 7% of people reported belching on Wegovy

The standard dosing schedule is: Weeks 14 : 0.25 mg once weekly (initial dose) Weeks 58 : 0.5 mg once weekly Weeks 912 : 1 mg once weekly Weeks 1316 : 1.7 mg once weekly Week 17 and onward : 2.4 mg once weekly (maintenance dose for adults and pediatric patients aged 12 years and older) This gradual increase reduces the risk of side effects like nausea and ensures the body adapts to the medication

Semaglutide is a single-pathway GLP-1 receptor agonist, while tirzepatide is a dual GLP-1/GIP receptor agonist that activates two incretin receptors at once

Smart supplementing is mostly about filling those gaps, not chasing a magic pill

People often start seeing measurable weight loss within the first month on semaglutide, with results accelerating through months 3 to 6